Technology
Health
Biotechnology

ChemoCentryx

$11.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (0.95%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ChemoCentryx and other stocks, options, ETFs, and crypto commission-free!

About

ChemoCentryx, Inc. Common Stock, also called ChemoCentryx, is a biopharmaceutical company engages in the development and commercialization of medicines. Read More It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

Employees
76
Headquarters
Mountain View, California
Founded
1996
Market Cap
675.97M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
328.48K
High Today
$11.96
Low Today
$11.58
Open Price
$11.70
Volume
215.75K
52 Week High
$14.98
52 Week Low
$9.07

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
Pharmaceutical
US
North America

News

Seeking AlphaMay 23

ChemoCentryx And Aurinia In Focal Segmental Glomerulosclerosis: Strength In Numbers

Due to the complexity and heterogeneity of FSGS, it is likely that more than one therapeutic agents including CCX140 may be needed to provide clinically effective benefits to FSGS patients.

10
Yahoo FinanceMay 9

Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI)

The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow.

42
The Motley FoolMay 7

ChemoCentryx Inc (CCXI) Q1 2019 Earnings Call Transcript

ChemoCentryx Inc (NASDAQ:CCXI) Q1 2019 Earnings Call , 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon and welcome to the ChemoCentryx First Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference will be recorded. I would now like to turn the call over to Bill Slattery of Burns McClellan. Mr...

17

Earnings

-$0.27
$0.09
$0.44
$0.80
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.